SMCI
Super Micro Computer
-- 40.210 PLTR
Palantir
-- 70.960 NVDA
NVIDIA
-- 140.260 TSLA
Tesla
-- 351.420 INTC
Intel
-- 22.470 
NEWS
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
Tuesday, 3rd December at 8:23 am
REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced that it has entered into a definitive agreement for the purchase and sale of 472,668 of the Company's American Depositary Shares ("ADSs"), each ADS representing 200 ordinary shares, at a purchase price of $6.00 per ADS, in a registered direct offering. The closing of the offering is expected to occur on or about December 4, 2024, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be approximately $2.8 million, before deducting the placement agent's fees and other offering expenses payable by the Company. Purple Biotech intends to use the net proceeds from the offering to fund the development of its oncology therapeutic candidates and for general working capital and corporate purposes.
Tuesday, 3rd December at 8:23 am
REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced that it has entered into a definitive agreement for the purchase and sale of 472,668 of the Company's American Depositary Shares ("ADSs"), each ADS representing 200 ordinary shares, at a purchase price of $6.00 per ADS, in a registered direct offering. The closing of the offering is expected to occur on or about December 4, 2024, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be approximately $2.8 million, before deducting the placement agent's fees and other offering expenses payable by the Company. Purple Biotech intends to use the net proceeds from the offering to fund the development of its oncology therapeutic candidates and for general working capital and corporate purposes.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Jaguar8 OP : Got shocked too
novice g : Is this good or bad?
BIG_TURRET : $6 for 200 Shares? Where's the line?![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
潇洒投一回 : After selling out, it will rise rapidly.